Navigation Menu

Skip to Navigation menu Skip to top of page

20 June 2008

Pfizer-Ranbaxy deal might signal trend

Eklavya Gupte, London

This week’s settlement of the Lipitor patent litigation suggests that branded and generic drugs companies are more willing to compromise on IP rights, according to lawyers spoken to by Managing IP

After five years of court battles, Pfizer and Indian generic manufacturer Ranbaxy Laboratories agreed to settle most of the Lipitor patent litigation worldwide on June 18.




The rest of this article is available to subscribers to Managing IP only.

Managing IP subscribers also have access to Managing Patents, Trade marks and Copyright until 30th October 2010.
Managing IP trialists have access to Managing Patents, Trade marks and Copyright for 48-hours.

Subscribe today for full access to this article. Alternatively, take a 48-hour free trial  giving you access to the current content. 

If you are already a subscriber please log in (see top right column) to access the rest of this article.